company background image
0IJO logo

Exelixis LSE:0IJO Stock Report

Last Price

US$23.74

Market Cap

US$7.2b

7D

1.8%

1Y

27.4%

Updated

25 Mar, 2024

Data

Company Financials +

0IJO Stock Overview

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.

0IJO fundamental analysis
Snowflake Score
Valuation4/6
Future Growth4/6
Past Performance4/6
Financial Health6/6
Dividends0/6

Exelixis, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Exelixis
Historical stock prices
Current Share PriceUS$23.74
52 Week HighUS$24.30
52 Week LowUS$18.20
Beta0.53
1 Month Change10.32%
3 Month Change-1.41%
1 Year Change27.40%
3 Year Change4.24%
5 Year Change35.11%
Change since IPO-21.57%

Recent News & Updates

Recent updates

Shareholder Returns

0IJOGB BiotechsGB Market
7D1.8%2.1%2.1%
1Y27.4%-29.8%3.8%

Return vs Industry: 0IJO exceeded the UK Biotechs industry which returned -27.1% over the past year.

Return vs Market: 0IJO exceeded the UK Market which returned 4.2% over the past year.

Price Volatility

Is 0IJO's price volatile compared to industry and market?
0IJO volatility
0IJO Average Weekly Movement3.6%
Biotechs Industry Average Movement7.8%
Market Average Movement4.8%
10% most volatile stocks in GB Market11.2%
10% least volatile stocks in GB Market2.5%

Stable Share Price: 0IJO has not had significant price volatility in the past 3 months.

Volatility Over Time: 0IJO's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19941,310Mike Morrisseyhttps://www.exelixis.com

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors.

Exelixis, Inc. Fundamentals Summary

How do Exelixis's earnings and revenue compare to its market cap?
0IJO fundamental statistics
Market capUS$7.21b
Earnings (TTM)US$207.77m
Revenue (TTM)US$1.83b

34.6x

P/E Ratio

3.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0IJO income statement (TTM)
RevenueUS$1.83b
Cost of RevenueUS$72.55m
Gross ProfitUS$1.76b
Other ExpensesUS$1.55b
EarningsUS$207.77m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0.69
Gross Margin96.04%
Net Profit Margin11.35%
Debt/Equity Ratio0%

How did 0IJO perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.